News

You are here

May 24, 2019

We are pleased to announce a new publication on the journal Biochimica et Biophysica Acta – Biomembranes titled "Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation". The study has been led by Dra.

Feb 11, 2019

11th February 2019. Double date: International Epilepsy Day and International Day of Women and Girls in Science, two very different events with a high social responsibility weight. Iproteos has joined both initiatives to raise awareness on Epilepsy and gender inequality in Science.

Apr 10, 2019

On Tuesday 30th of April 2019, Iproteos will celebrate an Ordinary General Meeting. More information is given in the link below.

El Martes 30 de Abril de 2019, Iproteos celebrará una Junta General Ordinaria. Se puede encontrar toda la información necesaria en el siguiente enlace:

JUNTA GENERAL ORDINARIA 30 ABRIL 2019

Feb 10, 2019

On Tuesday, 9th of April 2019, Iproteos will celebrate the Trade Union assembly. More information is given in the link below.

El martes 9 de Abril de 2019, Iproteos celebrará una Asamblea del Sindicato de Voto. Se puede encontrar toda la información necesaria en el siguiente enlace: 

ASAMBLEA DEL SINDICATO 9 ABRIL 2019

Jan 11, 2019

San Francisco hosted this week the 11thBiotech Showcase and the 37th Annual JP Morgan Healthcare Conference. These two spaces are created with the objective of bringing together thousands of industry leaders, innovators and top members of the investment community from around the world. 

Nov 29, 2018

Iproteos, IBEC and the Vall d’Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.

It’s a family of peptidomimetic drugs based on a totally new anti-tumor action mechanism, the result of several years of research by Pere Roca-Cusachs’ group at IBEC.

The Translational Research Group on Cancer in Children and Teenagers at VHIR will evaluate candidate drugs, developed with Iproteos’ IPROTech technology, in pediatric tumours in vitro and in vivo.

The project, which received €935,000 from the Ministry of Science, Innovation and Universities through of the call Retos Colaboración, will focus in its first phase on two of the most common solid tumors in children and adolescents, rhabdomyosarcoma and neuroblastoma, as well as in lung and colon cancer, which have the highest mortality rate in adults.